Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V C Jordan

Showing results (341-350 of 365) with videos related to

Pageof 37
Sort By:
British Journal of Cancer|December 1, 1991
Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouseY Iino, D M Wolf, S M Langan-Fahey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic miceE S Lee, J M Schafer, K Yao, et al.
Cancer Research|September 18, 2001
Molecular classification of estrogensV C Jordan, J M Schafer, A S Levenson, et al.
Endocrinology|May 1, 1985
Rat uterine growth and induction of progesterone receptor without estrogen receptor translocationV C Jordan, A C Tate, S D Lyman, et al.
Breast Cancer (Tokyo, Japan)|October 9, 2008
Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapyR M O'Regan, G M England, J I Macgregor, et al.
Carcinogenesis|March 1, 1996
The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesisY P Dragan, S Fahey, E Nuwaysir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancerF R Ahmann, D L Citrin, H A deHaan, et al.
Journal of the National Cancer Institute|August 15, 1990
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancerR R Love, P A Newcomb, D A Wiebe, et al.
British Journal of Cancer|August 15, 2002
Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alphaA S Levenson, I L Kliakhandler, K M Svoboda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenograftsJ M Schafer, E S Lee, R C Dardes, et al.
Pageof 37

Showing results (341-350 of 365) with videos related to

Sort By:
Pageof 37
British Journal of Cancer|December 1, 1991
Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouseY Iino, D M Wolf, S M Langan-Fahey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic miceE S Lee, J M Schafer, K Yao, et al.
Cancer Research|September 18, 2001
Molecular classification of estrogensV C Jordan, J M Schafer, A S Levenson, et al.
Endocrinology|May 1, 1985
Rat uterine growth and induction of progesterone receptor without estrogen receptor translocationV C Jordan, A C Tate, S D Lyman, et al.
Breast Cancer (Tokyo, Japan)|October 9, 2008
Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapyR M O'Regan, G M England, J I Macgregor, et al.
Carcinogenesis|March 1, 1996
The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesisY P Dragan, S Fahey, E Nuwaysir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancerF R Ahmann, D L Citrin, H A deHaan, et al.
Journal of the National Cancer Institute|August 15, 1990
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancerR R Love, P A Newcomb, D A Wiebe, et al.
British Journal of Cancer|August 15, 2002
Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alphaA S Levenson, I L Kliakhandler, K M Svoboda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenograftsJ M Schafer, E S Lee, R C Dardes, et al.
Pageof 37